VEGFA and colorectal carcinoma: An open-label, multicenter, phase II clinical trial (NCT04715633) evaluating the PD-1 inhibitor camrelizumab combined with the VEGF inhibitor apatinib for the treatment of locally advanced CRC with dMMR/MSI-H is ongoing.